Interpace Biosciences, Inc. Stock price Other OTC
Equities
IDXG
US46062X3035
Managed Healthcare
Financials (USD)
Sales 2021 | 41.31M | Sales 2022 | 31.84M | Capitalization | 4.44M |
---|---|---|---|---|---|
Net income 2021 | -14M | Net income 2022 | -22M | EV / Sales 2021 | 1.01 x |
Net Debt 2021 | 10.65M | Net Debt 2022 | 11.26M | EV / Sales 2022 | 0.49 x |
P/E ratio 2021 |
-2.06
x | P/E ratio 2022 |
-0.2
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 72.25% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 20-11-30 |
Director of Finance/CFO | 32 | 19-05-31 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 22-01-31 |
Joseph Keegan
BRD | Director/Board Member | 71 | 15-12-31 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 04-08-31 |
1st Jan change | Capi. | |
---|---|---|
-17.53% | 5.66B | |
+2.67% | 1.34B |